<DOC>
	<DOCNO>NCT00251589</DOCNO>
	<brief_summary>The reason study find safe maximum tolerate dose oral vorinostat combination erlotinib [ Tarceva ( TM ) ] give patient lung cancer relapse failed therapy disease . Once safe maximum tolerate dose vorinostat determine , patient enrol clinical trial continue vorinostat erlotinib 8 month . Safety effectiveness also evaluate .</brief_summary>
	<brief_title>A Phase I/II Clinical Trial Vorinostat Combination With Erlotinib Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer ( 0683-025 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Males females 18 year age old confirm diagnosis nonsmallcell lung cancer ( NSCLC ) fail least one prior treatment NSCLC . Patients must prove disease CT scan MRI . Patients must least 4 week chemotherapy cancer surgery treatment use investigational drug . Patients must 2 week radiation therapy . At screen patient must normal lab result pregnant . Women men must agree practice adequate birth control study . Patient ability understand sign consent form . Patient prior treatment vorinostat erlotinib . Patient follow condition : active infection include hepatitis B C , unstable brain metastasis , swallow difficulty , heart problem , significant eye abnormality , drug alcohol abuse , mental illness pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Relapsed Non-Small-Cell Lung Cancer</keyword>
	<keyword>Refractory Non-Small-Cell Lung Cancer</keyword>
</DOC>